Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up...

Descripción completa

Detalles Bibliográficos
Autores principales: Papapoulos, Socrates, Chapurlat, Roland, Libanati, Cesar, Brandi, Maria Luisa, Brown, Jacques P, Czerwiński, Edward, Krieg, Marc-Antoine, Man, Zulema, Mellström, Dan, Radominski, Sebastião C, Reginster, Jean-Yves, Resch, Heinrich, Ivorra, José A Román, Roux, Christian, Vittinghoff, Eric, Austin, Matthew, Daizadeh, Nadia, Bradley, Michelle N, Grauer, Andreas, Cummings, Steven R, Bone, Henry G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415620/
https://www.ncbi.nlm.nih.gov/pubmed/22113951
http://dx.doi.org/10.1002/jbmr.1479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415620/
https://www.ncbi.nlm.nih.gov/pubmed/22113951
http://dx.doi.org/10.1002/jbmr.1479

Ejemplares similares